After Statins, Rise Of The Subgroups? IMPROVE-IT Suggests Population Choice Key
Executive Summary
Diabetics seem to have benefited from Zetia, but not rest of high-risk patients in IMPROVE-IT – suggesting next-step cholesterol drugs might wind up being targeted to subgroups.